Guangzhou Wondfo Biotech Co Ltd (300482) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.021x

Based on the latest financial reports, Guangzhou Wondfo Biotech Co Ltd (300482) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥116.99 Million ≈ $17.12 Million USD) by net assets (CN¥5.56 Billion ≈ $813.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Guangzhou Wondfo Biotech Co Ltd (300482) total market value for the company's overall valuation and market capitalisation.

Guangzhou Wondfo Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Guangzhou Wondfo Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guangzhou Wondfo Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore 300482 cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Grupa Pracuj S.A.
WAR:GPP
0.138x
Eerly Govt Ppty Inc
NYSE:DEA
0.020x
Jiuzhitang Co Ltd
SHE:000989
0.027x
Wangneng Environment Co Ltd
SHE:002034
0.073x
Chongqing Taiji Industry Group Co Ltd
SHG:600129
0.112x
Elbit Systems Ltd
TA:ESLT
0.081x
Tellhow Sci-Tech Co Ltd
SHG:600590
0.050x
AXWAY SOFTWARE EO 2
F:1XV
N/A

Annual Cash Flow Conversion Efficiency for Guangzhou Wondfo Biotech Co Ltd (2011–2025)

The table below shows the annual cash flow conversion efficiency of Guangzhou Wondfo Biotech Co Ltd from 2011 to 2025. View today's stock price for Guangzhou Wondfo Biotech Co Ltd for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥5.47 Billion
≈ $800.95 Million
CN¥463.04 Million
≈ $67.76 Million
0.085x +32.15%
2024-12-31 CN¥5.65 Billion
≈ $826.81 Million
CN¥361.71 Million
≈ $52.93 Million
0.064x -23.90%
2023-12-31 CN¥4.61 Billion
≈ $675.26 Million
CN¥388.19 Million
≈ $56.80 Million
0.084x -77.31%
2022-12-31 CN¥4.54 Billion
≈ $663.99 Million
CN¥1.68 Billion
≈ $246.15 Million
0.371x +95.36%
2021-12-31 CN¥3.50 Billion
≈ $512.76 Million
CN¥664.93 Million
≈ $97.30 Million
0.190x -46.50%
2020-12-31 CN¥2.99 Billion
≈ $438.06 Million
CN¥1.06 Billion
≈ $155.38 Million
0.355x +181.66%
2019-12-31 CN¥2.46 Billion
≈ $360.06 Million
CN¥309.86 Million
≈ $45.34 Million
0.126x +9.42%
2018-12-31 CN¥2.15 Billion
≈ $314.82 Million
CN¥247.61 Million
≈ $36.23 Million
0.115x -18.89%
2017-12-31 CN¥1.19 Billion
≈ $174.13 Million
CN¥168.85 Million
≈ $24.71 Million
0.142x +8.28%
2016-12-31 CN¥854.75 Million
≈ $125.08 Million
CN¥112.01 Million
≈ $16.39 Million
0.131x -30.35%
2015-12-31 CN¥700.64 Million
≈ $102.53 Million
CN¥131.81 Million
≈ $19.29 Million
0.188x -43.56%
2014-12-31 CN¥313.43 Million
≈ $45.86 Million
CN¥104.47 Million
≈ $15.29 Million
0.333x -20.24%
2013-12-31 CN¥241.47 Million
≈ $35.33 Million
CN¥100.91 Million
≈ $14.77 Million
0.418x +1.91%
2012-12-31 CN¥182.48 Million
≈ $26.70 Million
CN¥74.84 Million
≈ $10.95 Million
0.410x +148.81%
2011-12-31 CN¥144.61 Million
≈ $21.16 Million
CN¥23.83 Million
≈ $3.49 Million
0.165x --

About Guangzhou Wondfo Biotech Co Ltd

SHE:300482 China Medical Devices
Market Cap
$1.09 Billion
CN¥7.42 Billion CNY
Market Cap Rank
#8575 Global
#2044 in China
Share Price
CN¥15.86
Change (1 day)
+0.57%
52-Week Range
CN¥15.55 - CN¥25.56
All Time High
CN¥92.01
About

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more